Portal de Periódicos da CAPES

Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease

2000; Wiley; Volume: 15; Issue: 3 Linguagem: Inglês

10.1002/1531-8257(200005)15

1531-8257

Hubert H. Fernandez, Margaret C. Lannon, Joseph H. Friedman, Bruce P. Abbott,

Neurological disorders and treatments

Movement DisordersVolume 15, Issue 3 p. 579-581 Clinical/Scientific Notes Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease Hubert H. Fernandez MD, Corresponding Author Hubert H. Fernandez MD Division of Neurology, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, U.S.A., Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode IslandMemorial Hospital of Rhode Island, Division of Neurology, 111 Brewster St., Pawtucket, RI 02860, U.S.A.Search for more papers by this authorMargaret C. Lannon RN, MS,, Margaret C. Lannon RN, MS, Division of Neurology, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, U.S.A.Search for more papers by this authorJoseph H. Friedman MD, Joseph H. Friedman MD Division of Neurology, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, U.S.A., Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode IslandSearch for more papers by this authorBruce P. Abbott MD, Bruce P. Abbott MD St. Luke's Hospital, New Bedford, Massachusetts, U.S.A.Search for more papers by this author Hubert H. Fernandez MD, Corresponding Author Hubert H. Fernandez MD Division of Neurology, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, U.S.A., Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode IslandMemorial Hospital of Rhode Island, Division of Neurology, 111 Brewster St., Pawtucket, RI 02860, U.S.A.Search for more papers by this authorMargaret C. Lannon RN, MS,, Margaret C. Lannon RN, MS, Division of Neurology, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, U.S.A.Search for more papers by this authorJoseph H. Friedman MD, Joseph H. Friedman MD Division of Neurology, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, U.S.A., Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode IslandSearch for more papers by this authorBruce P. Abbott MD, Bruce P. Abbott MD St. Luke's Hospital, New Bedford, Massachusetts, U.S.A.Search for more papers by this author First published: 31 January 2001 https://doi.org/10.1002/1531-8257(200005)15:3 3.0.CO;2-0Citations: 34AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1Friedman JH. Levodopa-induced psychosis. Neuropharmacology 1991; 14: 283– 295. 2Fernandez HH, Friedman JH. The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs 1999; 11: 467– 483. 3Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 42: 2227– 2229. 4Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56: 566– 559. 5Jimenez-Jimenez FJ, Tallon-Barranco A, Orti-Pareja M, Zurdo M, Porta J, Molina JA. Olanzapine can worsen parkinsonism. Neurology 1998; 50: 1183– 1184. 6Friedman JH, Goldstein SM. Olanzapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease. Neurology 1998; 50: 1195– 1196. 7Molho ES, Factor SA. Worsening of motor features of parkinsonism with olanzapine. Mov Disord 1999; 14: 1014– 1016. 8Rosebush PI, Mazurek MF. Neurological side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 1999; 52: 782– 785. 9Fernandez HH, Friedman JH, Jacques C, Rosenfield M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 1999; 14: 484– 487. 10Juncos JL, Evatt ML, Jewart D. Long Term effect of quetiapine fumarate in parkinsonism complicated by psychosis. Neurology 1998; 50(suppl 4): A70– 71. 11Parsa M, Bastani B. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. Neuropsychiatry 1998; 10: 1– 4. 12Saller CF, Salama AL. Seroquel: biochemical profile of a potential atypical antispychotic. Psychopharmacology (Berl) 1993; 112: 285– 292. 13Carey G, Bergamn J. Discriminative stimulus effects of proposed atypical antipsychotics in clozapine-trained squirrels and monkeys [Abstract]. Behav Pharmacol 1994; 5: 114. 14Small JG, Hirsch SR, Arvanitis LA, Miller BH, Linic CG. Quetiapine in patients with schizophrenia. A high and low-dose double blind comparison with placebo. Arch Gen Psychiatry 1997; 54: 549– 557. 15Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group. Multiple fixed doses of 'Seroquel'(quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233– 246. 16 Physicians' Desk Reference, 54th ed. Montvale, NJ: Medical Economics Company, Inc, 2000:252–253. 17Bennett JPJr, Landrow ER, Schuh LA. Suppressors of dyskinesia in advanced Parkinson's disease. II: increasing daily clozapine doses suppress dyskinesias and improve motor symptoms. Neurology 1993; 43: 1551– 1555. 18Bennett JPJr, Landrow ER, Schuh LA. Suppressors of dyskinesia in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 1994; 9: 409– 414. 19Friedman JH, Koller WC, Lannon MC, et al. Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology 1997; 48: 1077– 1081. 20Bonuccelli U, Ceravolo R, Salvetti S, et al. Clozapine in Parkinson's disease tremor: effects of acute and chronic administration. Neurology 1997; 49: 1587– 1590. Citing Literature Volume15, Issue3May 2000Pages 579-581 ReferencesRelatedInformation